Core Viewpoint - Agenus Inc. is set to host its first Stakeholder Webcast of 2026, focusing on the global momentum of its botensilimab and balstilimab (BOT+BAL) program as it enters the new year [1][2]. Group 1: Webcast Details - The webcast will take place on January 28, 2026, at 4:00 p.m. ET and will feature insights from Agenus leadership and an international oncology expert [1][2]. - The session will include a live Q&A, allowing stakeholders to submit questions in advance [3]. Group 2: Featured Topics and Speakers - Garo Armen, PhD, will discuss a recent strategic collaboration with Zydus Lifesciences, emphasizing its role in strengthening Agenus' global development and patient access programs for BOT+BAL [4]. - Professor Robin Jones will provide a clinical perspective on the expansion of France's Autorisation d'Accès Compassionnel (AAC) program to include sarcoma patients, highlighting the unmet medical needs in this area [5]. - José Iglesias, MD, will address the expansion of Agenus' global medical affairs organization and its support for authorized access pathways as the BOT+BAL program progresses through Phase 3 evaluation [6]. Group 3: Company Overview - Agenus is a leading immuno-oncology company with a comprehensive pipeline of immunological agents, founded in 1994 [8]. - The company aims to expand patient populations benefiting from cancer immunotherapy through various therapeutic approaches, including antibody therapeutics and adoptive cell therapies [8]. Group 4: Product Information - Botensilimab is designed to enhance anti-tumor immune responses and has shown clinical responses across nine metastatic, late-line cancers, with approximately 1,200 patients treated in clinical trials [10][11]. - Balstilimab is a fully human monoclonal antibody that blocks PD-1 and has been evaluated in over 900 patients, demonstrating clinical activity across several tumor types [12].

Core Insights - Agenus Inc. announced promising clinical results for botensilimab plus balstilimab (BOT+BAL) in treating platinum-refractory ovarian cancer, indicating significant clinical activity in a challenging patient population [1][2][3] Clinical Results - The BOT+BAL combination achieved a 23% overall response rate and a 31% clinical benefit rate, with a median duration of response of 9.7 months and a median overall survival of 14.8 months, with 75% of patients alive at 12 months [3][4] - The study involved 44 women with treatment-refractory ovarian cancer, with nearly 75% being platinum-resistant or platinum-refractory, demonstrating activity across various ovarian cancer subtypes [8] Unmet Medical Need - Ovarian cancer results in approximately 13,000 deaths annually in the U.S. and 200,000 globally, with poor outcomes for patients with platinum-resistant tumors, highlighting the urgent need for effective therapies [5] Safety Profile - The BOT+BAL combination exhibited a manageable safety profile, with common treatment-related adverse events including diarrhea/colitis (43%; 16% grade 3), fatigue, and nausea (36%), all effectively managed [8] Future Development - BOT+BAL is advancing through global clinical development for multiple tumor types, with access available through regulatory-authorized early access mechanisms in certain countries [9]